
Rational Pharmacotherapy in Cardiology, Journal Year: 2023, Volume and Issue: 19(6), P. 597 - 602
Published: Dec. 28, 2023
Dyslipidemia is one of the most significant modifiable cardiovascular risk factors. The change in modern paradigm for dyslipidemia treatment from high-intensity statin therapy to lipid-lowering makes it possible more often use new drug classes achieve target level low-density lipoprotein cholesterol. article presents two case reports on inclisiran as part combination secondary prevention patients at very high risk. Based presented cases, following clinical aspects management are discussed: safety achieving cholesterol levels below 1 mmol/l a patient with asymptomatic cerebral infarction, need adequate after revascularization, strategic importance prescribing cerebrovascular disease reduce risk, adherence aspect effective control.
Language: Английский